Better Health, Brighter Future





Takeda Pharmaceutical Company Strategic Update

33rd Annual J.P. Morgan Healthcare Conference

Christophe Weber President & Chief Operating Officer

Takeda Pharmaceutical Company Limited

Forward-Looking Statements



This presentation contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future.

All forward-looking statements are based on judgments derived from the information available to the Company at this time. Forward looking statements can sometimes be identified by the use of forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "continue," "seek," "pro forma," "potential," "target, " "forecast," or "intend" or other similar words or expressions of the negative thereof.

Certain risks and uncertainties could cause the Company's actual results to differ materially from any forward looking statements contained in this presentation. These risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding the Company's business, including general economic conditions in the US and worldwide; (2) competitive pressures; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) decisions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates; and (8) integration activities with acquired companies.

We assume no obligation to update or revise any forward-looking statements or other information contained in this presentation, whether as a result of new information, future events, or otherwise.



I. Strategic Roadmap Global Organization

II. Sustaining Sales Growth

III. Leadership in Oncology and Gastroenterology (GI)



I. Strategic Roadmap Global Organization

II. Sustaining Sales Growth

III. Leadership in Oncology and Gastroenterology (GI)

Takeda Strategic Roadmap to Deliver Sustainable EPS Growth



Takeda-ism
 Patient → Trust → Reputation → Business

- Patient and customer centricity
- Global and agile organization fostering talent
- Focused world class innovation engine (R&D)
- Sustaining sales growth

Innovation with leadership in GI & Oncology Leverage value brands in Emerging Markets

• Financial discipline

Profitable Growth & Creation of Shareholder Value





Become an agile, best-in-class global pharmaceutical company focused on patients and customers


- Values based
- Agile
- Simple, with clear accountabilities
- Patient- and customer-centric
- Talent development and diversity champion

Takeda-ism: Key to our Reputation and Business Success





Takeda-ism is our foundation as we focus on:



Takeda's Strengths and Areas for Improvement



	 Takeda-ism
What we	 Dedicated and talented employees
possess -	 Attractive late stage pipeline assets
Takeda assets	 Leading position in Japan
/ strengths	Global reach
	 Long-term perspective
	 Patients and customer centricity
	· Talients and customer centrolly
	 Organization – clear accountability / ownership
What we need	,
What we need to improve	 Organization – clear accountability / ownership
	 Organization – clear accountability / ownership Way we work – to achieve "Global One Takeda"

Focus to Support Growth



Linitian and a second s	FOUR Therapeutic Areas Units in R&D	 Gastroenterology (GI) Oncology Central Nervous System (CNS) Cardiovascular/Metabolic (CVM)
Change and a start	TWO Global Specialty Business Units	OncologyVaccine (incl. R&D)
	FIVE Regional Business Units	 Japan Pharmaceuticals Emerging Markets U.S. EUCAN (Europe + Canada) Japan Consumer Healthcare
	Global Manufa	cturing & Quality

Business Partner organization

Takeda's Executive Team





Yasuchika Hasegawa Chairman & CEO



Christophe Weber President & COO



Shinji Honda Corporate Strategy Officer

Christophe

Bianchi

President



Masato Iwasaki President Japan Pharmaceuticals ΒU

Doug Cole President **US Business Unit**




Yoshihiro Nakagawa Global General Counsel

Global Oncology BU



Marc Princen















Thomas Wozniewski

Global Manufacturing and Supply Officer





Communications and Public Affairs Officer



Andy Plump Chief Medical and Scientific Officer Designate will join Feb 1st



I. Strategic Roadmap Global Organization

II. Sustaining Sales Growth

III. Leadership in Oncology and Gastroenterology (GI)

Two Powerful Growth Engines



INNOVATIVE PRODUCTS

4 THERAPEUTIC AREAS and VACCINES

US, Europe, Japan and Emerging Markets


VALUE BRANDS

BRANDED GENERICS and OTC

Emerging Markets


Emerging Markets: Value Brands, a Strong Foundation to Launch Innovative Products





Promising Portfolio that is Increasingly Focused, Innovative and Global






Assets shown are in Phase 2 or later and have the most substantial financial expectations

New Product Launches and Value Brands Significantly Outpace LOE Impact






* This graph was drafted before entry of colchicine competitors and AG

More Balanced Geographic Share






* This graph was drafted before entry of colchicine competitors and AG

Offset Generic Erosion in Japan through New Product Launches





Takeda Pharmaceutical Company Limited




I. Strategic Roadmap Global Organization

II. Sustaining Sales Growth

III. Leadership in Oncology and Gastroenterology (GI)


Takeda Oncology





GI: A fast growing market





*Defined as IBD and HPB sub-TAs and select specialty GI indications within motility (e.g., IBS, gastroparesis, functional dyspepsia) SOURCE: 2014 EvaluatePharma data, Evaluate Ltd., www.evaluategroup.com; team analysis

Takeda is a Global GI Leader






ENTYVIO[®]: A Promising Take-off








TAKECAB[®] (vonoprazan): A New Class of Acid Secretion Inhibitor



Mechanism	Potassium-competitive acid blocker (P-CAB)
Indications	Acid-related diseases (approved in Japan, December 2014)

- True competitive antagonist of H+, K+-ATPase, acid not required for activation
- Fast-acting, strong and sustained effect
- Co-promotion agreement with Otsuka in Japan

High accumulation and long retention in the gastric parietal cell





Takeda-ism based, patient centric, global organization Global commercial reach and launch capability

Growth driven by Innovation

GI and Oncology are key mid term growth drivers

Value brands in Emerging Markets

Financial discipline

Efficiency driven by globalization Project Summit Cost efficiency and operating leverage Strong balance sheet Focus on total shareholder return

We are focusing on growth and financial discipline to create value for shareholders

Profitable

Growth

Better Health, Brighter Future

THANK YOU



Takeda Pharmaceutical Company Limited